A composition useful for treating immune-mediated inflammatory diseases or cancer in mammalian subjects is disclosed. The composition comprises a synergistic combination of a cannabis derived compound, and a medicinal mushroom.

Provided are oxygenated Cannabis skin therapy compositions, and methods for preparing the compositions by ozonating coconut oil, extracting medicinal/recreational Cannabis into coconut oil to yield a Cannabis infused coconut oil, and combining the ozonated coconut oil with the Cannabis infused coconut oil to yield the skin therapy compositions.

The present invention relates to a composition comprising delta-9-tetrahydrocannabinol (THC), alpha-bisabolol, guaiol, beta-caryophyllene and at least one terpene selected from the group consisting of linalool, alpha-humulene, nerolidol, caryophyllene oxide, alpha-pinene, camphene, beta-pinene, beta-myrcene, limonene, eucalyptol, ocimene, gamma-terpinene, terpinolene, alpha-terpinene, para-cymene, isopulegol and geraniol. The invention also relates to a pharmaceutical formulation comprising such composition. The pharmaceutical formulation according to the present invention may be used in medicine, specifically in the treatment and/or prevention of diseases associated with pain such as chronic cancer pain, somatic pain, visceral pain, central neuropathic pain, peripheral neuropathic pain or complex pain syndromes.

The present disclosure is directed to a beverage composition comprising from a cannabis extract and a Hericium erinaceus extract. The present disclosure also relates to methods of reducing a withdrawal symptom and/or reducing an addictive behavior comprising administering a therapeutically effective amount of the aforementioned beverage composition to a subject having the withdrawal symptom and/or the addictive behavior, methods for treating alcoholism in a subject comprising administering a therapeutically effective amount of the aforementioned beverage composition to the subject, and method of producing altered perception and/or reduced stress while ameliorating a side effect of THC overconsumption in a subject comprising administering a therapeutically effective amount of the aforementioned beverage composition to the subject.

Compositions and methods of use of treatment of one or more of ovarian cancer, endometrial cancer, head and neck cancer, noncancerous gynecological disorders, and estrogen sensitive cancers, the composition comprising an effective amount of a cannabinoid and a flavonoid wherein the method comprises administering to a patient in need thereof an effective amount of the composition and optionally administering the composition concomitantly with a chemotherapeutic agent.

Provided is a composition including a dispersion medium including: an aqueous solution; a first active ingredient; a flavor agent; and a first type of polymer; and a dispersed phase including: a population of particles, each particle including: a core including: a second active ingredient a second type of polymer; and an aqueous solution; a shell, substantially surrounding the core, the shell including: a third type of polymer; a plurality of lipophilic carriers; and a third active ingredient; and a plurality of emulsifying agents.

Disclosed are compositions containing chemical constituents from plants, uses of these compositions and methods for making them. In various embodiments, the present invention relates to an improved modes of administration of herbal remedies.

A medicinal chewing gum has an inner core containing a first gum base and a first cannabinoid in a lipophilic nanosized form and an outer layer containing a second gum base and a second cannabinoid in a hydrophilic nanosized form, thereby providing quick release of the second cannabinoid in the outer layer and sustained release of the first cannabinoid in the inner layer. At least one of the inner core and the outer layer contains a synergistic compound having a synergistic effect with at least one of the first and second cannabinoids in the treatment of a medical condition. At least one of the first cannabinoid and the second cannabinoid are a cannabinoid other than cannabidiol (CBD).

Tailored chromatographic media and methods for using the tailored chromatographic media to purify mixtures extracted from cannabis to obtain a cannabinoid having greater than about 90% purity. In an embodiment, the tailored chromatographic media may comprise a porous resin and/or porous carbon and have a surface area of greater than about 900 m2/g, wherein the tailored chromatographic media may further comprise micropores, mesopores, macropores, wherein the tailored chromatographic media may further comprise at least two distributions of macroporous pore sizes, wherein the at least two distributions of macroporous pore sizes may comprise a first population having a macroporous pore size denoted x and a second population having a macroporous pore size denoted y, wherein a ratio of x/y may be about 1:1, and wherein the tailored chromatographic media may further comprise an anionic polysaccharide and a functional moiety.

Homogeneous extract-infused cannabis biomasses, methods for their preparation, and products produced therefrom, such as pre-rolled joints, are provided. An exemplary method comprises steps of providing a cannabis extract; heating the cannabis extract; providing a milled cannabis plant material; applying the heated cannabis extract to the milled cannabis plant material using a predefined ratio of the cannabis plant material to the heated cannabis extract to provide an extract-applied plant material; and mixing the extract-applied plant material to provide a homogeneous extract-infused cannabis biomass, wherein there is less than a 15% variability in a target concentration of the at least one biomass cannabinoid, the at least one biomass terpene, or any combination thereof throughout a prepared batch and/or between alternate batches of the homogeneous extract-infused cannabis biomass.